Literature DB >> 10358205

Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice.

D B Stevens1, K Chen, R S Seitz, E E Sercarz, J M Bronstein.   

Abstract

Oligodendrocyte-specific protein (OSP) is a recently isolated and cloned, 207-aa, hydrophobic, four-transmembrane protein found in CNS myelin. It represents approximately 7% of total myelin protein. The OSP cDNA sequence has no significant homology with previously reported genes, but the predicted protein structure suggests that OSP is a CNS homologue of peripheral myelin protein-22. We previously reported the presence of anti-OSP Abs in the cerebrospinal fluid of relapsing-remitting multiple sclerosis (MS) patients, but not control patient groups. In this study, we tested the ability of a panel of 20-mer peptides with 10-aa overlaps, representing the sequence of murine OSP, to induce experimental autoimmune encephalomyelitis (EAE), an animal model for MS. SJL mice challenged with murine OSP peptides 52-71, 82-101, 102-121, 142-161, 182-201, and 192-207 exhibited clinical EAE. OSP:52-71 elicited severe relapsing-remitting EAE in some individuals. All other encephalitogenic peptides elicited, at most, a loss of tail tonicity from which the mice most often completely recovered. Mononuclear cell infiltrates and focal demyelination characteristic of EAE were evident. T cell proliferative responses were seen with all encephalitogenic peptides except 142-161 and 182-201. OSP peptides 72-91 and 132-151 did not cause clinical EAE, but did elicit robust proliferative responses. B10.PL and PL/J mice challenged with the same OSP peptide doses as SJL mice did not exhibit clinical EAE. These results in the SJL EAE model, together with the results from MS patient clinical samples, make OSP a promising candidate for autoantigenic involvement in MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358205

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene.

Authors:  Ming-Chao Zhong; Nicole Kerlero de Rosbo; Avraham Ben-Nun
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Claudin Proteins And Neuronal Function.

Authors:  Jérôme Devaux; Bozena Fykkolodziej; Alexander Gow
Journal:  Curr Top Membr       Date:  2010       Impact factor: 3.049

4.  'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides.

Authors:  Nathali Kaushansky; Nicole Kerlero de Rosbo; Rina Zilkha-Falb; Reut Yosef-Hemo; Lydia Cohen; Avraham Ben-Nun
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

5.  Hydrocephalus and arthrogryposis in an immunocompetent mouse model of ZIKA teratogeny: A developmental study.

Authors:  Jose Xavier-Neto; Murilo Carvalho; Bruno Dos Santos Pascoalino; Alisson Campos Cardoso; Ângela Maria Sousa Costa; Ana Helena Macedo Pereira; Luana Nunes Santos; Ângela Saito; Rafael Elias Marques; Juliana Helena Costa Smetana; Silvio Roberto Consonni; Carla Bandeira; Vivian Vasconcelos Costa; Marcio Chaim Bajgelman; Paulo Sérgio Lopes de Oliveira; Marli Tenorio Cordeiro; Laura Helena Vega Gonzales Gil; Bianca Alves Pauletti; Daniela Campos Granato; Adriana Franco Paes Leme; Lucio Freitas-Junior; Carolina Borsoi Moraes Holanda de Freitas; Mauro Martins Teixeira; Estela Bevilacqua; Kleber Franchini
Journal:  PLoS Negl Trop Dis       Date:  2017-02-23

6.  Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis.

Authors:  Lillian A Buhler; Ramsey Samara; Esther Guzman; Carole L Wilson; Liljana Krizanac-Bengez; Damir Janigro; Douglas W Ethell
Journal:  BMC Neurosci       Date:  2009-03-06       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.